Who is sponsoring NCT04993924?

NCT04993924 is sponsored by Assaf-Harofeh Medical Center.

What condition does NCT04993924 study?

NCT04993924 studies IVF, Ovarian Cysts.

What drugs are being tested in NCT04993924?

Interventions: Cetrorelix Acetate, Ganerelix Acetate.

What is the status of NCT04993924?

NCT04993924 is currently UNKNOWN.

Last reviewed 2021-10-13 · How we verify

GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst

NCT04993924 PHASE4 UNKNOWN

In this study we would like to examine the effect of GnRH antagonist administration at the beginning of the follicular phase in patient presenting with a simple ovarian cyst 25-50 mm. The aim of this intervention is to allow a spontaneous regression of the ovarian cyst (if in nature) while ensuring a pituitary downregulation to prevent the beginning of a leading follicle recruitment. As previous studies using GnRH antagonist pre-treatment prior to GT initiation for other purposes demonstrated positive results (including different patient population) , no deleterious effects are expected.

Details

Lead sponsor	Assaf-Harofeh Medical Center
Phase	PHASE4
Status	UNKNOWN
Enrolment	15
Start date	Sat May 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

IVF
Ovarian Cysts

Interventions

Cetrorelix Acetate, Ganerelix Acetate

Countries

Israel